The U.S. Food and Drug Administration (FDA) has approved Stivarga to treat advanced colorectal cancer that has spread despite prior treatment. As a multi-kinase inhibitor, Stivarga is "designed to block enzymes that promote cancer growth." Despite side effects including weakness, fatigue, loss of appetite, infection, and possible liver problems, studies have indicated that patients taking Stivarga "lived an average of 6.4 months, compared with people given a placebo who lived an average of five months."
For more information, click here.
No comments:
Post a Comment